RxDoctor Payments Data

Stephen Dewey, MD

Family Medicine · Fishers, INNPI 1265415574

Payments from drug & device makers

$752in general payments, 2019–2025

Across 38 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$190
  • Lilly USA, LLC$172
  • AbbVie$78
  • AstraZeneca$51
  • Takeda Pharmaceuticals U.S.A., Inc.$39
  • Amgen$36
  • plus $187 from 11 others

What the payments were for

  • Food & beverage$752100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$752 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$67,455
Medicare patients
148
Services billed
880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$56,903
OzempicSemaglutide21$30,973
TrulicityDulaglutide12$22,052
JanuviaSitagliptin Phosphate13$11,728
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$11,626
Atorvastatin Calcium301$2,099
Fluticasone Propionate46$1,793
Omeprazole80$1,298
Gabapentin67$1,252
Escitalopram Oxalate92$1,219
Levothyroxine Sodium152$1,166
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$1,097
Amlodipine Besylate208$1,093
Tamsulosin Hcl65$1,071
Metformin Hcl ErMetformin Hcl89$936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$190$30,97321 claims
Lilly USA, LLCTrulicity$172$22,05212 claims
AbbVieSynthroid$78$39211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Fishers

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →